856851-34-8

Basic information

• Product Name: 2,6-Diamino-3-iodopyridine
• Synonyms: 2,6-Diamino-3-iodopyridine
• CAS NO: 856851-34-8
• Molecular Formula: C₅H₆IN₃
• Molecular Weight: 235.03
• Mol File: 856851-34-8.mol
• Article Data: 10

Chemical Properties

• Melting Point: 125 °C
• Boiling Point: 363.0±42.0 °C(Predicted)
• Appearance: /
• Density: 2.150±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 3.77±0.50(Predicted)
• CAS DataBase Reference: 2,6-Diamino-3-iodopyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 2,6-Diamino-3-iodopyridine(856851-34-8)
• EPA Substance Registry System: 2,6-Diamino-3-iodopyridine(856851-34-8)

Safety Data

• Hazardous Substances Data: 856851-34-8(Hazardous Substances Data)

Usage

Description

2,6-Diamino-3-iodopyridine is an organic compound that serves as an intermediate in the synthesis of various pharmaceutical compounds. It is characterized by the presence of two amino groups and an iodine atom attached to a pyridine ring, which contributes to its unique chemical properties and potential applications in the medical field.

Uses

Used in Pharmaceutical Industry:
2,6-Diamino-3-iodopyridine is used as an intermediate in the synthesis of 3-Phenylphenazopyridine (P336120), which is an impurity of Phenazopyridine (P313751). Phenazopyridine is an azo dye that is used in the treatment of urinary tract infections, providing relief from pain and discomfort associated with these conditions.
Additionally, 2,6-Diamino-3-iodopyridine is used as an analgesic for urinary tract infections. Its chemical structure allows it to target specific receptors and pathways involved in pain transmission, offering effective pain relief and improving the overall quality of life for patients suffering from these infections.

Upstream product

• 141-86-6 2.6-diaminopyridine 

Relevant articles and documents

5-HETEROARYL-PYRIDIN-2-AMINE CONFOUNDS AS NEUROPEPTIDE FF RECEPTOR ANTAGONISTS

The present invention relates to novel aminopyridine derivatives of the general formula (I) and pharmaceutical compositions comprising these compounds, as well as their therapeutic use, particularly as neuropeptide FF (NPFF) receptor antagonists, including, e.g., for the treatment or prevention of pain, opioid-induced hyperalgesia, or addiction.

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I); and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Discovery and Optimization of Selective Nav1.8 Modulator Series That Demonstrate Efficacy in Preclinical Models of Pain

Voltage-gated sodium channels, in particular Nav1.8, can be targeted for the treatment of neuropathic and inflammatory pain. Herein, we described the optimization of Nav1.8 modulator series to deliver subtype selective, state, and use-dependent chemical matter that is efficacious in preclinical models of neuropathic and inflammatory pain. (Chemical Presented).